Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2021-03-25 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
2020年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Self-Evaluation Report" for the year 2020 by 贝达药业股份有限公司. It discusses the company's internal control system, evaluation scope, methodology, control activities, risk assessment, and the conclusion that no material internal control deficiencies were found. The document is detailed and contains substantive content about internal control evaluation rather than just an announcement or summary. It is not a full annual report (10-K), audit report (AR), or earnings release (ER), but rather a specialized report on internal control evaluation, which aligns with the definition of an Audit Report / Information (AR) as it relates to internal control results and applied principles. The document length (over 11,000 characters) and detailed content confirm it is the report itself, not just an announcement. Therefore, the most appropriate classification is AR (Audit Report / Information). FY 2020
2021-03-25 Chinese
2020年度独立董事述职报告（JIANGNAN CAI)
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's 2020 Annual Work Report" for Betta Pharmaceuticals Co., Ltd. It details the independent director's attendance at board meetings, opinions on various company proposals, committee work, investigations, investor protection efforts, training, and exercising special powers during the year 2020. The content focuses on the independent director's duties and activities rather than presenting financial statements or audit results. It is a detailed report on board/management activities and governance-related work by an independent director. There is no indication that this is an annual report (10-K), audit report (AR), or any other financial report. The document is not a brief announcement or a proxy solicitation. Therefore, the best fitting category is Board/Management Information (MANG), which covers announcements of changes or reports related to the company's board or senior management activities, including independent director reports.
2021-03-25 Chinese
2020年度独立董事工作报告（赵骏)
Management Reports Classification · 95% confidence The document is titled as an "Independent Director's 2020 Annual Work Report" for Betta Pharmaceuticals Co., Ltd. It details the independent director's attendance at board meetings, opinions on various company matters including stock issuance and financial reports, committee work, investigations, investor protection efforts, training, and exercising special powers. The content is a detailed narrative of the independent director's activities and opinions during the year 2020, focusing on governance and oversight rather than financial results or audit findings. It is not a full annual report (10-K), audit report (AR), or earnings release (ER). It is also not a simple announcement or certification. The document fits best as a Management Report or similar detailed explanation of governance and oversight activities by management or board members. Therefore, the most appropriate classification is Management Reports (MDA). The document length (3764 characters) is sufficient for a substantive report, not a brief announcement.
2021-03-25 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of 贝达药业股份有限公司 regarding the approval of various reports and proposals related to the 2020 fiscal year, including the 2020 financial statements, annual report, internal control self-evaluation report, supervisory board work report, fundraising usage report, profit distribution plan, and auditor appointment. The document contains voting results and states that these reports are disclosed elsewhere on the official disclosure website. The document length is 2885 characters, which is relatively short and mainly summarizes approvals and resolutions rather than containing the full reports or detailed financial data. It also repeatedly states that the full reports are disclosed on the official website, indicating this document is an announcement of meeting resolutions and approvals rather than the reports themselves. Therefore, it fits best as a Regulatory Filing (RNS) because it is a formal announcement of supervisory board meeting resolutions and approvals related to annual reports and financial matters, but does not contain the full annual report or detailed financial statements itself.
2021-03-25 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 16th meeting of the 3rd Board of Directors of Betta Pharmaceuticals Co., Ltd. It includes multiple agenda items such as approval of the 2020 annual financial statements, the 2020 annual report, profit distribution plan, remuneration for directors and senior management, internal control self-assessment report, and other corporate governance matters. The document also mentions that these items will be submitted to the 2020 annual shareholders' meeting for approval. The content is typical of a Board/Management Information announcement, focusing on board meeting decisions and approvals rather than the full annual report itself. The document length is about 4962 characters, which is substantial but the content is clearly about board meeting resolutions rather than the full annual report or audit report. Therefore, the appropriate classification is Board/Management Information (MANG).
2021-03-25 Chinese
年报披露提示性公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement (332 characters) indicating that the full 2020 Annual Report and summary have been disclosed on a regulatory website. It explicitly states the report is available elsewhere and urges investors to review it there. There is no actual financial data or detailed report content included in this text. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA), not the Annual Report itself.
2021-03-25 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.